Skip to main
IRON
IRON logo

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc's positive outlook is supported by a substantial increase in the prevalence estimates of erythropoietic protoporphyria (EPP), with a 214% rise over the last 15 years and an annual growth rate of approximately 8%. The company's pipeline, particularly the therapy bitopertin, has demonstrated promising clinical results, including a 40% reduction in the disease-causing toxic metabolic intermediate PPIX, which bolsters the potential for commercial success in treating EPP. Furthermore, the ongoing trials, such as those for myelofibrosis, are expected to further validate Disc Medicine's innovative therapies and enhance investor confidence through anticipated beneficial updates in hemoglobin levels and overall disease management.

Bears say

Disc Medicine Inc faces a challenging outlook due to the potential failure to meet clinical requirements, which could adversely impact sales estimates and hinder revenue generation. The company’s forecasts for bitopertin sales in erythropoietic porphyrias, while optimistic, suggest a possible overestimation compared to consensus estimates, indicating a risk of market penetration issues amidst competitive pressures and pricing dynamics. Additionally, a higher-than-anticipated number of diagnosed EPP patients may not translate into a sufficient market for reimbursement or effective commercialization, further complicating the financial landscape for the company.

IRON has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 11 analysts, IRON has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.